Evidence map›Paper›PMID 36176916›Full record

ArticleActa pharmaceutica Sinica. B2022

Multi-functional vesicles improve

Xiaonan Chen, Yiqing Zou, Shuqi Zhang, Pengchao Fang, Shuxuan Li, Pengyu Li, Yingying Sun, Gang Yuan, Haiyan Hu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Nanomaterials: A Prospective Strategy for Biofilm-FormingInternational journal of nanomedicine · 2025
    Review
  4. Opportunities forMicroorganisms · 2024
    Review
  5. Article
  6. An antibiotic-free platform for eliminating persistentActa pharmaceutica Sinica. B · 2024
    Article
  7. Metal-Based Nanoparticles: A Prospective Strategy forInternational journal of nanomedicine · 2023
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xiaonan ChenLab of Pharmaceutics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Yiqing ZouLab of Pharmaceutics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Shuqi ZhangLab of Pharmaceutics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Pengchao FangLab of Pharmaceutics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Shuxuan LiLab of Pharmaceutics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Pengyu LiLab of Pharmaceutics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Yingying SunLab of Pharmaceutics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Gang YuanPhase I Clinical Trial Center, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.
Haiyan HuLab of Pharmaceutics, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BiofilmsBiofilms eradication tetralogyHelicobacter pyloriImmune evasionIntracellular bacteriaIn vivoLipid raftPharmaceutical preparations

Identifiers

PMID36176916
PMCPMC9513559
OpenAlexW4280503353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.